ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

As von Eschenbach Prepares For New Assignment, NCI’s 2015 Goal Faces Uncertainty. New Strategic Plan Lists Steps to 2015. “The Vision Is Within Our Grasp,” von Eschenbach Says.

March 10, 2006

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

January 31, 1992

Clinical Instigator Object To HEW Proposal On Compensation Notification In Consent Forms

December 15, 1978

Atlas Showing County Cancer Rates Available

July 18, 1975

Patient’s Husband To Fund Fellowship At Dana-Farber

September 8, 1995

Importation Is Remedy of Last Resort in Effort to Obtain Generic Injectables

March 2, 2012